Epidemiological, clinical, and therapeutic aspects of primary intracerebral hemorrhage

Alfonso Ciccone, Mario Pozzi, Cristina Motto, Pietro Tiraboschi, Roberto Sterzi

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Primary intracerebral hemorrhage is the least treatable form of stroke and is associated with high mortality rates. In the thrombolytic era, the attention has bee driven on the first hours of onset, when the hematoma is still growing. Intervention with ultra-early hemostatic therapy might arrest ongoing bleeding. Even if recombinant activated factor VII administered within 4 h of symptom onset did not improve outcome in a recent phase 3 trial, it reduced hematoma growth. Therefore, the rational for ultra-early hemostatic therapy it is still valid and another trial on hemostatic treatment is warranted.

Original languageEnglish
JournalNeurological Sciences
Volume29
Issue numberSUPPL. 2
DOIs
Publication statusPublished - Sep 2008

Fingerprint

Cerebral Hemorrhage
Hemostatics
Secondary Prevention
Hematoma
Factor VIIa
Bees
Therapeutics
Stroke
Hemorrhage
Mortality
Growth

Keywords

  • Hemostatic treatment
  • Primary intracerebral hemorrhage
  • Randomized controlled trial
  • Recombinant activated factor VII
  • Tranexamic acid

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Dermatology

Cite this

Epidemiological, clinical, and therapeutic aspects of primary intracerebral hemorrhage. / Ciccone, Alfonso; Pozzi, Mario; Motto, Cristina; Tiraboschi, Pietro; Sterzi, Roberto.

In: Neurological Sciences, Vol. 29, No. SUPPL. 2, 09.2008.

Research output: Contribution to journalArticle

Ciccone, Alfonso ; Pozzi, Mario ; Motto, Cristina ; Tiraboschi, Pietro ; Sterzi, Roberto. / Epidemiological, clinical, and therapeutic aspects of primary intracerebral hemorrhage. In: Neurological Sciences. 2008 ; Vol. 29, No. SUPPL. 2.
@article{1f230ab4c54846b1a08e78ad41feb7ff,
title = "Epidemiological, clinical, and therapeutic aspects of primary intracerebral hemorrhage",
abstract = "Primary intracerebral hemorrhage is the least treatable form of stroke and is associated with high mortality rates. In the thrombolytic era, the attention has bee driven on the first hours of onset, when the hematoma is still growing. Intervention with ultra-early hemostatic therapy might arrest ongoing bleeding. Even if recombinant activated factor VII administered within 4 h of symptom onset did not improve outcome in a recent phase 3 trial, it reduced hematoma growth. Therefore, the rational for ultra-early hemostatic therapy it is still valid and another trial on hemostatic treatment is warranted.",
keywords = "Hemostatic treatment, Primary intracerebral hemorrhage, Randomized controlled trial, Recombinant activated factor VII, Tranexamic acid",
author = "Alfonso Ciccone and Mario Pozzi and Cristina Motto and Pietro Tiraboschi and Roberto Sterzi",
year = "2008",
month = "9",
doi = "10.1007/s10072-008-0955-9",
language = "English",
volume = "29",
journal = "Neurological Sciences",
issn = "1590-1874",
publisher = "Springer-Verlag Italia s.r.l.",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Epidemiological, clinical, and therapeutic aspects of primary intracerebral hemorrhage

AU - Ciccone, Alfonso

AU - Pozzi, Mario

AU - Motto, Cristina

AU - Tiraboschi, Pietro

AU - Sterzi, Roberto

PY - 2008/9

Y1 - 2008/9

N2 - Primary intracerebral hemorrhage is the least treatable form of stroke and is associated with high mortality rates. In the thrombolytic era, the attention has bee driven on the first hours of onset, when the hematoma is still growing. Intervention with ultra-early hemostatic therapy might arrest ongoing bleeding. Even if recombinant activated factor VII administered within 4 h of symptom onset did not improve outcome in a recent phase 3 trial, it reduced hematoma growth. Therefore, the rational for ultra-early hemostatic therapy it is still valid and another trial on hemostatic treatment is warranted.

AB - Primary intracerebral hemorrhage is the least treatable form of stroke and is associated with high mortality rates. In the thrombolytic era, the attention has bee driven on the first hours of onset, when the hematoma is still growing. Intervention with ultra-early hemostatic therapy might arrest ongoing bleeding. Even if recombinant activated factor VII administered within 4 h of symptom onset did not improve outcome in a recent phase 3 trial, it reduced hematoma growth. Therefore, the rational for ultra-early hemostatic therapy it is still valid and another trial on hemostatic treatment is warranted.

KW - Hemostatic treatment

KW - Primary intracerebral hemorrhage

KW - Randomized controlled trial

KW - Recombinant activated factor VII

KW - Tranexamic acid

UR - http://www.scopus.com/inward/record.url?scp=53649091448&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53649091448&partnerID=8YFLogxK

U2 - 10.1007/s10072-008-0955-9

DO - 10.1007/s10072-008-0955-9

M3 - Article

VL - 29

JO - Neurological Sciences

JF - Neurological Sciences

SN - 1590-1874

IS - SUPPL. 2

ER -